DAYTON, OH – Premier Health is offering eligible patients with advanced pancreatic cancer access to daraxonrasib, an investigational targeted therapy that has shown promising results in clinical studies and is generating significant interest among oncology specialists.
Through a national Expanded Access Program (EAP), Premier Health is currently providing eligible patients access to daraxonrasib before potential FDA approval and broader commercial availability. Daraxonrasib is an oral therapy designed to target specific genetic mutations associated with tumor growth in many pancreatic cancers.
In May 2026 published clinical studies, investigators reported encouraging results, including improved survival outcomes among eligible patients…